3rd Quarter - Report

VIATRIS INC. for VIATRIS INC

Period 3rd Quarter 2012 Filed Oct 23, 2012 Signed by Lara Ramsburg, VP Government Relations

Official filing
Firm
VIATRIS INC.
Client
VIATRIS INC
Income
—
Expenses
$453,520
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Patent Settlements

LobbyistCovered position, as disclosed
LARA RAMSBURG —

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Health Issues HCR

S 1884 (School Access to Emergency Epinephrine); HR 6433 FDA User Fee Correction Act; Patent settlements; Serialization; Issues related to HIV/AIDS: Funding for antiretrovirals, PEPFAR, Global Fund, FDA; Issues related to biogenerics; Issues related to the generic drug industry

LobbyistCovered position, as disclosed
BRUCE LOTT —
DANIEL LUBOWITZ New —
LARA RAMSBURG —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6433 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.